Camile is a medtech executive and board director with a background in healthcare, medical research, industry and academia spanning 30 years. Camile trained as a clinician-scientist and holds degrees and fellowships in pathology, oncology, higher education, business management and leadership. He is a prolific author and international speaker and has been ranked in the World’s Top 2% of scientists since 2020. Camile held various senior public and private clinical, research, and academic appointments before transitioning to industry. 

Camile is currently CEO and managing director of Optiscan Imaging Ltd (ASX:OIL), an Australian publicly traded medical technology company which develops, manufactures, and commercializes digital pathology and precision surgery hardware and software solutions enabling live optical biopsy for diagnostic and surgical applications. At Optiscan’s core is its patent-protected portfolio of miniaturized confocal laser endomicroscopes that allow immediate informed clinical decisions based on real-time microscopic imaging of tissue. Camile has expanded Optiscan’s geographical footprint and raised capital for an extended portfolio of point-of-care surgical and digital pathology products to tackle large addressable markets, including breast, head & neck, gastrointestinal, robotic and veterinary imaging. Under his leadership, Optiscan is undergoing a digital transformation, developing a cloud-based telepathology streaming platform and AI/ML solutions for intraoperative digital workflows, and an endomicroscopic imaging system for robotic-assisted surgery.